This section is dedicate to all types of European Initiatives that are related to the research on rare diseases.
EU-OPENSCREEN, the European infrastructure for Chemical Biology, offers access to a distributed research infrastructure for scientists seeking a better understanding on how fundamental molecular processes act to govern biological function at the organismal, tissue, cellular and pathway levels. Partners in the EU-OPENSCREEN network have experience in the development of disease specific in-vitro assays based on primary cells, iPS lines and gene editing approaches which can be used to identify or further characterise novel compounds including repurposing approaches.
Which services are provided?
- Access to a unique European compound collection
The EU-OPENSCREEN compound collection is composed of proprietary compounds collected from European chemists as well as of selected commercial compounds characterized for a basic standard set of properties. Repurposing collections of FDA approved drugs and clinical development stage compounds are also available for translational efforts.
- High-throughput screening
EU-OPENSCREEN network of state-of-the-art high-throughput screening facilities can help you to screen its large compound collection compliant for the discovery of bioactive substances (‘hit’ compounds) for a wide spectrum of druggable targets and disease relevant phenotypic assays.
- Chemical optimization and profiling of preliminary ‘hits’
EU-OPENSCREEN can provide necessary service for comprehensive characterization (physicochemical and biological properties) and optimization of your identified preliminary ‘hit’ compounds to translate them into valuable (selective, potent) research tools.
- Training and education activities
EU-OPENSCREEN trains platform staff and users to improve quality of research.
Why to work with EU-OPENSCREEN?
The majority of scientists in Europe do not have access to suitable technology platforms and compound collections, which are generally expensive to purchase, operate and maintain. As a large-scale research infrastructure (RI) with an ‘open’ pre-competitive character, EU-OPENSCREEN will cost-effectively overcome this limitation by: involving and providing access to Europe’s leading screening platforms and chemistry groups; offering a jointly used rationally designed compound collection; and operating an open-access bioactivity database which will be accessible on a global basis. EU-OPENSCREEN offers to support you through the application process and beyond for rare disease research funding involving screening projects.
How much does it cost?
A screening project at a typical EU-OPENSCREEN screening site will cost 50-250k€
Countries involved in EU-OPENSCREEN:
Czech Republic; Denmark; EMBL; Finland; France; Germany; Greece; Hungary; The Netherlands; Norway; Poland; Romania; Spain; Sweden
EU-OPENSCREEN headquarters contact point:
Leibniz-Institut für Molekulare Pharmakologie (FMP) im Forschungsverbund Berlin e.V.
13125 Berlin, Germany
Phone: +49 (0)30 9479 3286
Fax: +49 (0)30 9479 3109
Find your national contact point by clicking on your country.
You have not found answers to your question, please send us your request and we will help you.
Looking for collaborations
For more information ABOUT E-Rare please contact:
Tel.: +33(0) 1 78 09 80 78
Agence Nationale de la Recherche - ANR
Health & Biology Department
50 Avenue Daumesnil
75012 Paris, France